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Takeshi Kondo,1,3 Masahiro Onozawa,1,3 Kaoru Kahata,1,3 Tomoyuki Endo,1,4 Shuichi Ota,3
Norihiro Sato,1,4 Mutsumi Takahata,1,3 Kohei Okada,1,3 Junji Tanaka,1,2 Satoshi Hashino,1,3
Mitsufumi Nishio,1,4 Takao Koike,4 Masahiro Asaka,3 Masahiro Imamura1,2Cytomegalovirus (CMV) infection is 1 of the major causes of morbidity in patients undergoing allogeneic
stem cell transplantation (allo-SCT). The incidences of CMV antigenemia and CMV disease in 43 patients
who received allogeneic bone marrow transplantation (BMT) using a reduced-intensity conditioning (RIC)
regimen, which mainly consisted of fludarabine (Flu), busulfan (Bu), and total body irradiation (TBI), were
compared with those in 68 patients who received a myeloablative conditioning (MAC) regimen, and risk fac-
tors for CMV antigenemia and CMV disease were identified. Before engraftment, grade 3-4 mucosal injury
because of the conditioning regimen was significantly decreased in RIC patients (stomatitis: P5.02; diarrhea:
P\.01). Rate of engraftment, incidences of acute graft-versus-host disease (aGVHD), and rate of cortico-
steroid administration were not different in RIC patients and MAC patients. Although the incidences of
CMV antigenemia were not significantly different in RIC patients and MAC patients (64.1% versus 57.8%,
log rank, P 5 .59), the incidence of CMV disease was significantly decreased in RIC patients (5.4% versus
20.3%, log rank, P 5 .04). CMV seropositivity in the patients (P\ .01) and corticosteroid administration
(P\ .01) were revealed by multivariate analysis to be significant risk factors for CMV antigenemia. Grade
II-IV aGVHD (P5 .02) and grade 3-4 diarrhea before engraftment (P5 .04) were revealed to be risk factors
for CMV disease. The present study is the first study to show that severe diarrhea before engraftment is
a significant risk factor for CMV disease. In summary, risk of CMV disease was significantly decreased in pa-
tients without severe mucosal injury of the gut because of the conditioning regimen before engraftment.
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6/j.bbmt.2009.02.006stem cell transplantation (allo-SCT). Preemptive anti-
viral therapy has been shown to reduce the risk of
CMV disease [1-3]. Major risk factors for CMV infec-
tion are serologic status of the donor and recipient,
graft-versus-host disease (GVHD), corticosteroid ad-
ministration, and T cell depletion [1,2,4-13]. Recently,
reduced-intensity conditioning (RIC) regimens have
been developed for patients who had been considered
ineligible for SCT using a myeloablative conditioning
(MAC) regimen because of advanced age or medical
contraindications [14,15]. Although many studies have
shown that infection before engraftment was reduced
inpatients undergoingRICbecauseof a shorter neutro-
penic period and less severe mucositis [16-19], risks of
CMV infection have not been substantially reduced af-
ter RIC-SCT [1,7,8,10-12]. Again, we need to consider
the difference in CMV infection depending on the RIC
regimen because various RIC protocols have been de-
veloped and the toxicity profile might vary from 1 pro-
tocol to another because of variability in the degree of679
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We should also consider the difference in CMV infec-
tion depending on the stem cell source [8,20].
The present study was a retrospective analysis to
compare the incidence of CMV infection in 43 consec-
utive patients who received bone marrow transplanta-
tion (BMT) using an RIC regimen, which mainly
consisted of fludarabine (Flu), busulfan (Bu), and
total body irradiation (TBI) (Flu/Bu/TBI) in our
institution with that in 68 patients who received
MAC-BMT during the same period. The risk factors
for CMV antigenemia and development of CMV dis-
ease were also investigated.PATIENTS AND METHODS
Patients
One hundred eleven consecutive adult patients
with advanced hematologic diseases who received
allogeneic BMT using RIC regimens (43 patients) or
MAC regimens (68 patients), between September
2000 and March 2007, at Hokkaido University Hospi-
tal were analyzed for CMV infections. Twenty-eight
patients received an RIC regimen because of advanced
age (.50 years), and 10 received an RIC regimen be-
cause of prior autologous transplantation (5 patients
overlapped with the patients of advanced age). A differ-
ence in the risk of CMV infection depending on stem
cell source has been reported [8,20], and we cannot use
peripheral blood stem cells (PBSC) from an unrelated
donor (PBSC can be used only from related donors) in
Japan. Moreover, it has been reported that cord blood
showed differences in the incidences of infections and
kinetics of immunologic recovery from other stem cell
sources. Therefore, we analyzed only patients who re-
ceived BMT. Patients who had already received alloge-
neic SCT were excluded from this study.Conditioning Regimens
In the RIC group, 38 (88.4%) of the patients re-
ceived a conditioning regimen of Flu/Bu/TBI, which
consisted of Flu at a dose of 30 mg/m2 once daily ad-
ministered intravenously (i.v.) on days27 to22 (total
dose: 180 mg/m2) and Bu at 1 mg/kg 4 times daily ad-
ministered orally (p.o.) on days23 and22 (total dose:
8 mg/kg) combined with fractionated TBI at 2 Gy
twice daily on day21 (total dose: 4 Gy), and the other
5 patients received Flu plus melphalan (mel; n 5 4) or
Flu plus cyclophosphamide (Cy) (n 5 1). In the MAC
group, 10 patients (14.7%) received a conditioning
regimen of Cy/TBI, which consisted of Cy at a dose
of 60 mg/kg once daily administered i.v. on days
25 and 24 combined with fractionated TBI at 2 Gy
twice daily on days 23 to 21 (total dose: 12 Gy), and
44 patients (64.7%) received Cy/TBI plus VP-16(VP/Cy/TBI), in which VP-16 was added to Cy/TBI
at a dose of 15 mg/kg once daily administered i.v. on
days 27 and 26 (total dose: 30 mg/kg) [21,22]. The
other patients received other regimens of Bu/Cy or
Cy/TBI plus cytarabine. GVHDprophylaxis consisted
of cyclosporine A (CsA) and a short course of metho-
trexate (MTX; 15 mg/m2 on day 1 and 10 mg/m2 on
days 3 and 6) for HLA-matched related donor recipi-
ents, and tacrolimus plus a short course of MTX was
given for HLA-matched unrelated donor or HLA-
mismatched donor (MMD) recipients. The patients
received GVHD prophylaxis from day 21 for 3
months, and drug doses were tapered in patients with
no active GVHD, the dose of CsA or tacrolimus being
adjusted by plasma level.
Supportive Care and Infection Prophylaxis
Levofloxacin (300 mg daily) was administered p.o.
for prevention of bacterial infections until engraftment,
and antifungals (fluconazole at 400 mg daily p.o., itra-
conazol capsules at 200 mg daily p.o., or micafungin
at 100 mg daily i.v.) were administered for prevention
of fungal infections. Oral acyclovir was given on day
27 to day 35 for prevention of herpes simplex virus
(HSV) infection. Oral trimethoprim-sulfamethoxazole
or pentamidine inhalation was started after engraft-
ment for prevention of Pneumocystis jiroveci infection.
Prophylactic intravenous immunoglobulin (10 g) was
given biweekly until serum IgG levels reached .400
mg/dL. Prednisolone was administered for patients
who developed grade $ii acute GVHD (aGVHD) at
a dose of 0.5-1.0 mg/kg daily according to a physician’s
decision. The dose of prednisolone administered was
lower than the dose used in other countries because
of the lower incidence of critical aGVHD in Japan [23].
CMV Surveillance and Treatment
Pretransplant serum samples from all patients and
donors were tested for serologic evidence of past infec-
tion with CMV by an enzyme-linked immunosorbent
assay or complement fixation test. When a patient
and a donor were both negative for CMV, patients re-
ceived CMV-negative blood products. When a patient
or a donor was positive for CMV, the patient was given
unscreened blood products. Surveillance blood CMV
pp65 antigenemia was monitored once or twice
a week between engraftment and day 100 post-SCT
[1,10,24]. Patients with persistent CMV infection,
GVHD, and/or corticosteroid administration were
screened beyond this period at the discretion of the
doctor [1,3]. When a patient developed respiratory
symptoms or abdominal symptoms suggestive of
CMV disease, bronchoalveolar lavage (BAL) or colo-
noscopy was performed to determine whether the
patient had CMV disease. The patients received pre-
emptive ganciclovir (GCV) at a dose of 5 mg/kg twice
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second day of 2 consecutive days on which patients
were negative for CMV antigenemia with clinical
improvement. Patients with aGVHD received main-
tenance therapy of GCV (5 mg/kg once daily) for 2
weeks. Foscavir was administered for patients who
showed rising CMV antigenemia, those who devel-
oped CMV disease despite GCV administration,
or those who developed serious toxicity because of
GCV.
Definitions
CMV antigenemia was considered positive if there
was more than 1 pp651 cell/104 neutrophils assessed.
CMV pneumonitis was defined as the demonstration
of CMV in tissue by culture or histology or in BAL
by culture, direct fluorescence antibody stain, or cytol-
ogy in the presence of new or changing pulmonary
infiltrates. However, detection of CMV by culture or
by cytology showed low sensitivity, and it was difficult
to perform lung biopsy because of complications after
SCT. Therefore, CMV pneumonitis was also defined
as the demonstration of all of the following factors:
detection of CMV by polymerase chain reaction
(PCR), respiratory symptoms, presence of new or
changing pulmonary infiltrates, and CMV antigene-
mia. CMV enteritis was diagnosed when gastrointesti-
nal signs or symptoms occurred, and evidence of CMV
in the gastrointestinal tract was diagnosed by culture,
immunohistochemistry, or in situ hybridization from
biopsy specimens [10]. CMV hepatitis was diagnosed
when liver dysfunction occurred, and evidence of
CMV in liver tissuewas diagnosed by culture, immuno-
histochemistry, or in situ hybridization from biopsy
specimens. aGVHD and chronic GVHD (cGVHD)
were graded by standard criteria [25,26]. Overall sur-
vival (OS) was calculated from the day of SCT until
death or last follow-up.
End Points and Statistical Analysis
The aims of this study were to compare the inci-
dences of CMV antigenemia and the incidences of
CMV disease in patients undergoing RIC and MAC
regimens and to identify risk factors. Univariate
analyses were performed using the chi-square test
and Fisher’s exact test, as appropriate. The probabi-
lities of CMV antigenemia, CMV disease, OS, and
progression-free survival (PFS) were estimated using
the Kaplan-Meier method. Effects of the conditioning
regimens on survival and CMV infections were studied
using the log rank test. Multivariate logistic regression
models were used to analyze the influence of selected
variables with the forward stepwise method on the
risk of CMV antigenemia and CMV disease. All
P-values were 2-sided, and a P-value of .05 was used
as the cutoff for statistical significance.RESULTS
Patient and Transplantation Characteristics
Patient and transplantation characteristics are
summarized in Table 1. Median age, GVHD prophy-
laxis, underlying disease, prior autologous transplanta-
tion, and months from diagnosis to transplantation
were significantly different between RIC patients and
MAC patients. CMV serostatus was not different be-
tween RIC patients and MAC patients.
Transplantation Outcomes
Transplantation outcomes are summarized in
Table 2. Stomatitis and diarrhea were assessed as reg-
imen-related mucositis, and grade $3 stomatitis and
grade $3 diarrhea were significantly less in RIC pa-
tients. Except for 1 patient who died early after en-
graftment, all patients who achieved engraftment
were assessed for aGVHD and CMV infection (RIC:
n5 39,MAC: n5 65). Although incidence of aGVHD
was not different between the groups, median onset
day of aGVHD was significantly delayed in RIC pa-
tients (day 33 versus day 20, P\ .01). The rate of cor-
ticosteroid administration and the median dose of
corticosteroid for GVHD (1 mg/kg prednisolone)
were the same in RIC patients and MAC patients,
but the median duration of corticosteroid therapy
was longer in RIC patients than in MAC patients
with marginal significance (RIC: median 180.5 days
[range: 39-975 days], MAC: 85 days [range: 20-404
days], P 5 .08). The median follow-up period was
18.1 months (range: 0.1-83.4 months) for all patients
and 30.3 months (range 8.1-83.4 months) for patients
alive. The 2-year OS was not different between the
groups. There was no difference between causes of
death in RIC patients and MAC patients (RIC: disease
progression, n 5 5; transplantation-related complica-
tion, n 5 8, versus MAC: disease progression,
n5 13; transplantation-related complication, n5 10).
CMVAntigenemia and CMV Disease (Table 2
and Figure 1)
Durations of CMV monitoring in RIC patients
and MAC patients were similar. Incidences of CMV
antigenemia were not different in RIC patients and
MAC patients (RIC: n 5 25 [64.1%] versus MAC:
n5 37 [57.8%], log rank, P5 .59), and the median on-
set day of CMV antigenemia was the same (day 43). In-
cidence of CMV disease was significantly decreased in
RIC patients (RIC: n5 2 [5.4%] versus MAC: n 5 13
[20.3%], log rank, P 5 .04, hazard ratio [HR] 0.24,
95% confidence interval [CI] 0.1-1.0). In the RIC
group, 69.4% and 0.0% of the CMV-seropositive
and CMV-seronegative patients, respectively,
developed CMV antigenemia, and no difference was
observed between RIC patients and MAC patients.
Table 2. Transplantation outocomes
RIC MAC P-Value
Grade$3 stomatitis
before engraftment
19.0% 41.5% 0.02
Grade$3 diarrhea
before engraftment
11.9% 34.4% <0.01
Engraftment 93.0% 95.6% 0.56
day, median (range) 16 (7-21) 15 (9-39) 0.81
Acute GVHD
overall 71.8% 78.5% 0.44
onset, median (range) 33 (18-127) 20 (8-59) <0.01
grade II-IV 41.0% 52.3% 0.26
grade III-IV 17.9% 15.4% 0.73
gastrontestinal aGVHD 30.8% 27.7% 0.70
Corticosteroid 46.2% 52.3% 0.54
CMV Antigenemia 64.1% 57.8% 0.59
onset, median (range) day 43 (16-86) day 43 (1-137)
CMV seropositive patient 69.4% 60.7% 0.39
CMV seronegative patient 0.0% 25.0% 0.62
CMV disease
overall 5.4% 20.3% 0.04
onset, median (range) day 45,185 day 47 (25-71)
CMV enteritis 2.7% 12.5% 0.20
CMV pneumonitis 2.7% 6.3% 0.75
PFS (2 y) 61.0% 58.0% 0.65
OS (2 y) 67.5% 65.0% 0.88
PFS indicates progression-free survival; OS, overall survivial; GVHD,
graft-verses-host-disease; CMV, cytomegalovirus; RIC, reduced-inten-
sity conditioning; MAC, myeloablative conditioning.
Table 1. Patients and transplantation characteristics
RIC (n 5 43) MAC (n 5 68) P-value
Age, median (range) 52 (17-66) 34.5 (15-58) <.01
Patient sex, %
Male 48.8% 63.2% .13
Underlying disease, %
Acute leukemia 16.3% 54.4% <.01
MDS 27.9% 10.3%
CML 9.3% 20.6%
ML/ATL 27.9% 10.3%
MM 11.6% 0.0%
Others 7.0% 4.4%
Prior autologous SCT, % 23.3% 0.0% <.01
Diagnosis to SCT, months;
median (range)
22.5 (1.7-240) 8.3 (5.0-276.1) <.01
CR at SCT, % 53.5% 68.7% .11
Donor, %
MRD 23.3% 30.9% .48
MUD 67.4% 55.9%
MMD 9.3% 13.2%
TBI, % 88.4% 91.2% .63
GVHD prophylaxis, %
CsA+MTX 44.2% 67.6% .02
TK+MTX 53.5% 30.9%
CMV serostatus, %
High risk (R+) 93.0% 88.2% .71
Intermediate risk
(R2/D+)
4.7% 8.8%
Low risk (R2/D2) 2.3% 2.9%
MDS indicates myelodysplastic syndrome; CML, chronic myelogenous
leukemia; ML, malignant lymphoma; ATL, adult T cell leukemia/
lymphoma; MM, multiple myeloma; SCT, stem cell transplantation; CR,
complete remission; MRD, HLA-matched related donor; MUD, HLA-
matched unrelated donor; MMD, HLA-mismatched donor; TBI, total
body irradiation; GVHD, graft-versus-host disease; CsA, cyclosporine
A; MTX, methotrexate; TK, tacrolimus; CMV cytomegalovirus; R, recip-
ient; D, donor. RIC, reduced-intensity conditioning; MAC, myeloablative
conditioning.
Figure 1. Cumulative incidences of CMVantigenemia (a) and CMV dis-
ease (b).
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teritis on day 45, and 1 (2.7%) of the RIC patients de-
veloped pneumonitis on day 185. In 11 patients who
developed both aGVHD and CMV disease, 9 patients
(81.8%) developed aGVHDearlier thanCMVdisease.
In MAC patients, 8 (12.5%) of the patients developed
enteritis, 4 (6.3%) of the patients developed pneumo-
nitis, and 1 (1.6%) of the patients developed hepatitis
on median day of 47 (days 25-71). All cases of enteritis
or hepatitis were diagnosed by tissue biopsy and im-
munohistochemical staining. No case was confirmed
by culture. Only 1 patient who received an RIC regi-
men developed CMV disease beyond day 100. There
was no difference in type of CMV disease between
RIC patients and MAC patients (P 5 .2 for enteritis,
P5 .7 for pneumonitis). Only 1 patient who developed
CMV pneumonitis following the MAC regimen died
of CMV infection.
Risk Factors for CMVAntigenemia and CMV
Disease (Table 3)
Univariate analysis showed that CMV seropositiv-
ity of patients at SCT, any grade of aGVHD,
gastrointestinal aGVHD, and corticosteroid adminis-
tration were risk factors for CMV antigenemia.CMV seropositivity of the patients and corticoster-
oid administration remained significant inmultivariate
analysis.
Analyses of risk factors for CMV disease were
also performed. In univariate analysis, MAC regimen,
Table 3. Univariate and multivariate analyses of risk factors for CMV antigenemia and CMV disease
Univariate Multivariate Univariate Multivariate
Variables CMV Antigenemia P Odds Ratio (95%CI) P CMV Disease P Odds Ratio (95%CI) P
Conditioning regimen
RIC 64.1% .52 5.4% .04
MAC 57.8% 20.3%
CMV serostatus (recipient)
Positive 64.1% .04 11.8 (2.4-58.0) <.01 15.6% .90
Negative 27.2% 9.1%
Diarrhea before engraftment (grade)
-2 59.5% .85 8.3% .04 4.1 (1.0-15.6) .04
3- 61.5% 26.9%
Acute GVHD, overall
Yes 67.9% <.01 13.4% .74
No 36.0% 8.3%
Acute GVHD, grade II-IV
Yes 72.0% .02 26.5% <.01 7.0 (1.4-35.8) .02
No 49.1% 3.8%
Acute GVHD, gastrointestinal
Yes 77.4% .02 32.1% <.01
No 53.4% 8.2%
Corticosteroid
Yes 78.4% <.01 8.3 (3.0-23.2) <.01 24.0% .01
No 42.3% 5.9%
CI indicates confidence intervea; GVHD, graft-verses-host-disease; CMV, cytomegalovirus; RIC, reduced-intensity conditioning; MAC, myeloablative
conditioning.
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aGVHD, gastrointestinal aGVHD, and corticosteroid
administration were revealed to be significant risk fac-
tors for development of CMV disease. Bacterial infec-
tion and fungal infections occurred in 28% and 11% of
the patients, respectively, and there were no differ-
ences in the incidences of CMV antigenemia (bacterial
infection, P5 .12; fungal infection, P5 .91) and CMV
diseases (bacterial infection, P 5 .34; fungal infection,
P 5 .41) between patients with bacterial infection or
fungal infection and patients without bacterial or fun-
gal infection. Grade 3-4 diarrhea before engraftment
and grade II-IV aGVHD remained significant in mul-
tivariate analysis. CMV disease did not occur in any of
the patients who had grade 3-4 diarrhea before en-
graftment without grade II-IV aGVHD (Figure 2,Figure 2. Cumulative incidence of CMV disease according to the com-
bination of 2 risk factors: grade II-IV aGVHD and grade 3-4 diarrhea be-
fore engraftment. Group A included patients who had both grade II-IV
aGVHD and grade 3-4 diarrhea before engraftment (n 5 15). Group
B included patients who had grade II-IV aGVHD, but did not develop
grade 3-4 diarrhea before engraftment (n 5 32). Group C included pa-
tients who did not develop grade II-IV aGVHD (n 5 52).Group C). However, in patients who developed grade
II-IV aGVHD, the incidence of CMV disease was di-
vided into 2 groups according to the presence of grade
3-4 diarrhea before engraftment (grade II-IV
aGVHD1/grade 3-4 diarrhea1 [Group A]: 46.7%
versus grade II-IV aGVHD1/grade 3-4 diarrhea2
[Group B]: 12.5%, logrank, P 5 .01 HR 4.01 [1.38-
18.54]).DISCUSSION
In this study, we analyzed the incidence and char-
acteristics of CMV infections in patients who received
allogeneic BMT after an RIC regimen of Flu/Bu/TBI,
and we compared the incidences of CMV antigenemia
and CMV disease in RIC patients and MAC patients.
CMV antigenemia developed in 64% of the RIC
patients, a higher incidence than the incidence found
in other studies (about 40%-50%) [1,8,10,11,13]. It
has been reported that the incidence of CMV activa-
tion was not reduced in RIC patients [1,7,8,10-12],
and reported risk factors for CMV infection in RIC
patients include CMV serostatus, HLA-matched un-
related donor, advanced age of donor, grade II-IV
aGVHD, corticosteroid administration, Campath-
1H and/or antithymocyte globulin (ATG) in the
conditioning regimen and BM as a stem cell source
[1,2,4-6,8-13,27,28]. In our study, all patients received
BM as a stem cell source, and the number of high-risk
patients of CMV serostatus in our study was larger
than that in other studies, which might explain the
higher incidence of CMV antigenemia. Multivariate
analysis in this study confirmed CMV serostatus and
684 Biol Blood Marrow Transplant 15:679-685, 2009A. Shigematsu et al.corticosteroid administration as significant risk factors
for CMV antigenemia.
Although the incidence of CMV antigenemia was
not decreased in RIC patients, CMV disease was de-
creased in RIC patients. The incidence of CMV dis-
ease in this study was not increased compared to that
in other studies, and it was significantly decreased in
RIC patients compared with that in MAC patients.
In the present study, grade II-IV aGVHD and grade
3-4 diarrhea before engraftment were revealed bymul-
tivariate analysis to be significant risk factors for devel-
opment of CMV disease. The incidences of grade
II-IV aGVHD and the median dose of corticosteroid
for GVHD in RIC patients and MAC patients were
the same. The median duration of corticosteroid ther-
apy was longer in RIC patients with marginal signifi-
cance. Therefore, we do not think that the incidence
of grade II-IV aGVHD and the intensity and the dura-
tion of immunosuppressants mainly contribute to the
higher incidence of CMV disease in MAC patients.
This is the first study to show an increased risk of
CMV disease among patients with severe diarrhea be-
cause of the conditioning regimen, which reflected
mucosal injury of the gut. Almost all of the CMV dis-
eases that occurred in our patients were CMV enteri-
tis; therefore, diarrhea was determined to be a risk
factor for CMV disease. The incidence of CMV anti-
genemia was not different between patients with grade
3-4 diarrhea and patients without grade 3-4 diarrhea.
Also, the incidences of grade II-IV aGVHD and gas-
trointestinal aGVHD were not different between pa-
tients with grade 3-4 diarrhea and patients without
grade 3-4 diarrhea (data not shown). These findings
suggested that severe diarrhea affected the incidence
of CMV disease directly, not via aGVHD. CMV dis-
ease occurred in 46.7% of the patients who developed
both grade 3-4 diarrhea and grade II-IV aGVHD, but
CMV disease occurred in only 12.5% of the patients
who developed grade II-IV aGVHD without grade
3-4 diarrhea. CMV disease occurred in only 1 patient
who had no grade II-IV aGVHD. These results sug-
gested that immunosuppression in the whole body
because of aGVHD (and corticosteroid) was most
important for ‘‘CMV reactivation,’’ but that mucosal
injury of the gut was also necessary for development
of ‘‘CMV disease.’’ It has been reported that mucosal
immunity of the gut is an important defensive system
against pathogens including CMV, and that immu-
noglobulin, macrophages, and T-lymphocytes play
a pivotal role in this local immunity. Therefore, im-
pairment of mucosal immunity of the gut because of
the conditioning regimen might have influenced the
incidence of CMV enteritis in our patients [29-31].
Risk of severe diarrhea before engraftment may be
complicated with our MAC regimen, which mainly in-
cluded VP-16 [22]. We should consider the increased
risk for development of CMV disease in patientswith severe diarrhea before engraftment and in these
patients who develop grade II-IV aGVHD. Although
our analysis has limitations because of its retrospective
fashion and small sample size, patients who received an
RIC regimen showed a lower risk of CMV disease, and
mucosal injury of the gut was determined to be a signif-
icant risk factor for development of CMV disease. Fur-
ther studies are needed to confirm these findings.ACKNOWLEDGMENTS
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